60
Participants
Start Date
January 1, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
August 30, 2027
Immunotherapy+radiotherapy
"Adjuvant Immunotherapy: Immunotherapy drug of choice is tirilizumab, which has received national recommendations in metastatic uroepithelial cancer. Tirelizumab 200mg Q3w; the duration of immunotherapy is recommended for at least 1 year.~Adjuvant radiotherapy can be given concurrently or sequentially with adjuvant immunotherapy; it is recommended that radiotherapy can be started within 4-6 weeks after surgery. Rotational intensity-modulated radiotherapy (VMAT), daily image-guided radiotherapy (Daily IGRT) techniques are used."
surveillance alone
Patients recieve surveillance alone without any adjuvant interventions until any disease progression endpoints occur.
RECRUITING
Departmeng of Urology, Peking University First Hospital, Beijing
RECRUITING
Department of Radiotherapy Oncology, Peking University First Hospital, Beijing
Peking University First Hospital
OTHER